Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
28.86
-0.08 (-0.28%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Company Description

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.

The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride.

Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam.

The company was incorporated in 2013 and is based in Shanghai, China.

Zai Lab Limited
Zai Lab logo
Country China
Founded 2013
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 1,869
CEO Ying Du

Contact Details

Address:
Jinchuang Plaza, Building 1, 4th Floor
Shanghai, 201210
China
Phone 86 21 6163 2588
Website zailaboratory.com

Stock Details

Ticker Symbol ZLAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001704292
CUSIP Number 98887Q104
ISIN Number US98887Q1040
SIC Code 2834

Key Executives

Name Position
Dr. Ying Du Ph.D. Founder, Chairperson and Chief Executive Officer
Joshua L. Smiley President and Chief Operating Officer
Dr. Rafael G. Amado M.D. President and Head of Global Research and Development
Dr. Yajing Chen Ph.D. Chief Financial Officer
Dr. Peter Huang Ph.D. Chief Scientific Officer
Christine Chiou Senior Vice President and Head of Investor Relations
Frazor Titus Edmondson III, J.D. Chief Legal Officer and Joint Corporate Secretary
Dr. Jonathan J. Wang MBA, Ph.D. Chief Business Officer
Dr. James Yan DABT, M.D., Ph.D. Chief Operating Officer of Research & Development
Tong Zhu Chief Commercial Officer of Greater China

Latest SEC Filings

Date Type Title
Apr 18, 2025 PRE 14A Other preliminary proxy statements
Apr 4, 2025 144 Filing
Apr 4, 2025 144 Filing
Apr 4, 2025 144 Filing
Apr 4, 2025 144 Filing
Apr 4, 2025 144 Filing
Apr 2, 2025 144 Filing
Apr 2, 2025 144 Filing
Apr 2, 2025 144 Filing
Apr 2, 2025 144 Filing